Immuno-Oncology | Specialty

Patient Selection for Nivolumab in HNSCC

December 22nd 2016

Nivolumab-Related Efficacy and Toxicity in HNSCC Patients

December 22nd 2016

Nivolumab: A New Standard-of-Care

December 22nd 2016

Immunotherapy for Recurrent HNSCC

December 22nd 2016

The Approval of Pembrolizumab for Recurrent HNSCC

December 22nd 2016

Immunotherapy for Virally Induced vs High-Mutation Burden HNSCC

December 22nd 2016

Mechanisms of Immunotherapy in HNSCC

December 22nd 2016

Historic Perspective on Recurrent HNSCC

December 22nd 2016

Historic Perspective on Systemic Therapy for Advanced HNSCC

December 22nd 2016

Multimodality Treatment for HNSCC

December 22nd 2016

Risk Stratification for HNSCC

December 22nd 2016

Biology of Head and Neck Squamous Cell Cancer (HNSCC)

December 22nd 2016

The Future of Driver Mutations in NSCLC

December 22nd 2016

Practical Experience With Dabrafenib/Trametinib in NCSLC

December 22nd 2016

Targeted Approaches in NSCLC: Lessons from Melanoma

December 22nd 2016

Patient Selection in BRAF-Mutant NSCLC

December 22nd 2016

The Evolving Mutational Landscape in NSCLC

December 22nd 2016

NSCLC: The BRAF/MEK Combination Safety Profile

December 22nd 2016

BRAF/MEK Efficacy in BRAF-mutant NSCLC

December 22nd 2016

Role of the MAP Kinase Pathway in NSCLC

December 22nd 2016